Cerenome (PSTV) Capital Expenditures (2010 - 2026)
Plus Therapeutics (PSTV) posted quarterly Capital Expenditures of $818000.0 for Q1 2026, up 27166.67% year-over-year from N/an in Q1 2025, and up 2626.67% quarter-over-quarter from $30000.0 in Q4 2025.
Cerenome (PSTV) Capital Expenditures (2010 - 2026) Analysis & Trends
Plus Therapeutics (PSTV) has reported Capital Expenditures for 17 consecutive years, with $818000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Capital Expenditures rose 27166.67% year-over-year to $818000.0; the TTM figure through Mar 2026 stood at $882000.0 (up 709.17% YoY), while the FY2025 annual figure was $67000.0, down 54.11% from the prior year.
- Capital Expenditures improved to $818000.0 in Q1 2026 per PSTV's latest filing, from $30000.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $3.0 million in Q4 2022 and bottomed at -$2.5 million in Q4 2023.
- Historically, Capital Expenditures has averaged $59000.0 across 5 years, with a median of $27000.0 in 2025.
- On a YoY basis, Capital Expenditures climbed as much as 30010.0% in 2022 and fell as far as 1933.33% in 2022.
- Plus Therapeutics' Capital Expenditures stood at $3.0 million in 2022, then plunged by 183.53% to -$2.5 million in 2023, then surged by 100.44% to $11000.0 in 2024, then surged by 172.73% to $30000.0 in 2025, then soared by 2626.67% to $818000.0 in 2026.
- Business Quant data shows PSTV's Capital Expenditures at $818000.0 in Q1 2026, $30000.0 in Q4 2025, and $27000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.75 Bn | 130.90 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.96 Bn | 77.96 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 64.98 Bn | 59.80 Bn | 1.37 Bn | - |
| 4 | Moderna | 56.33 Bn | 51.19 Bn | 52.00 Mn | 37.00 Mn |
| 5 | BeOne Medicines | 42.03 Bn | 36.93 Bn | 1.53 Bn | 25.02 Mn |
| 6 | Alnylam Pharmaceuticals | 31.56 Bn | 28.25 Bn | 992.69 Mn | 34.68 Mn |
| 7 | BioNTech SE | 27.74 Bn | 9.35 Bn | 668.28 Mn | -73.57 Mn |
| 8 | Insmed | 27.47 Bn | 26.31 Bn | 358.27 Mn | 6.26 Mn |
| 9 | Royalty Pharma | 27.32 Bn | 26.49 Bn | - | 251.02 Mn |
| 10 | Cerenome | 28.07 Mn | 19.48 Mn | - | 499,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 818,000.00 |
| Mar 31, 2026 | 818,000.00 |
| Dec 31, 2025 | 30,000.00 |
| Dec 31, 2025 | 30,000.00 |
| Sep 30, 2025 | 27,000.00 |
| Sep 30, 2025 | 27,000.00 |
| Jun 30, 2025 | 7,000.00 |
| Jun 30, 2025 | 7,000.00 |
| Mar 31, 2025 | 3,000.00 |
| Mar 31, 2025 | 3,000.00 |
| Dec 31, 2024 | 11,000.00 |
| Dec 31, 2024 | 11,000.00 |
| Sep 30, 2024 | 14,000.00 |
| Sep 30, 2024 | 14,000.00 |
| Jun 30, 2024 | 81,000.00 |
| Jun 30, 2024 | 81,000.00 |
| Mar 31, 2024 | 40,000.00 |
| Mar 31, 2024 | 40,000.00 |
| Dec 31, 2023 | -2.52 Mn |
| Dec 31, 2023 | -2.52 Mn |